Dedifferentiated chondrosarcoma: Prognostic factors and outcome from a European group

Grimer, R. J.; Gosheger, Georg; Taminiau, Antonie; Biau, David; Matéjovský, Z; Kollender, Yehuda; San-Julián, Mikel; Gherlinzoni, F.; Ferrari, C.

doi:10.1016/j.ejca.2007.06.016

Cited by 202 publications

(252 citation statements)

References 13 publications

Supporting

Mentioning

219

Contrasting

Unclassified

Order By: Relevance

“…One study seemed to show an effect on survival [77], which was not confirmed by others [37,78,79]. For peripheral dedifferentiated chondrosarcoma, arising in osteochondroma, chemotherapy led to longer survival in a small retrospective report [80].…”

Section: Systemic Treatmentmentioning

confidence: 99%

“…Dedifferentiated chondrosarcoma is a high-grade noncartilaginous sarcoma next to a (usually low-grade) malignant cartilage-forming tumor, with a remarkably sharp junction between the two components [36]. The tumor bears a dismal prognosis [37]. The rare genetic reports on dedifferentiated chondrosarcoma demonstrate that both components share identical genetic aberrations [38,39], with additional genetic changes in the anaplastic component [38 -41], indicating a common precursor cell with early diversion of the two components.…”

Section: Rare Chondrosarcoma Subtypesmentioning

confidence: 99%

See 1 more Smart Citation

The Clinical Approach Towards Chondrosarcoma

et al. 2008

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Classify the chondrosarcoma subtypes.2. Engage in the diagnostic process of chondrosarcoma.3. Evaluate the treatment options for chondrosarcoma.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com CME CME ABSTRACTThis review provides an overview of the histopathology, classification, diagnostic procedures, and therapy of skeletal chondrosarcoma. Chondrosarcomas that arise de novo are primary chondrosarcomas, whereas chondrosarcomas developing superimposed on pre-existing benign cartilage neoplasms such as enchondromas or osteochondromas are referred to as secondary chondrosarcomas. Conventional chondrosarcomas can be categorized according to their location in bone into central, peripheral, and juxtacortical chondrosarcomas. Histological grading is related to prognosis; however, it is also subject to interobserver variability. Rare subtypes of chondrosarcoma, including dedifferentiated, mesenchymal, and clear cell chondrosarcoma, are discussed as well. Magnetic resonance imaging is necessary to delineate the extent of the intraosseous and soft tissue involvement preoperatively. Computed tomography is especially recommended in the pelvis and other flat bones where it may be difficult to discern the pattern of bone destruction and the presence of matrix mineralization. Wide, en-bloc excision is the preferred surgical treatment in intermediate-and high-grade chondrosarcoma. In low-grade chondrosarcoma confined to the bone, extensive intralesional curettage followed by local adjuvant treatment and filling the cavity with bone graft has promising long-term clinical results and satisfactory local control. Chondrosarcomas are relatively radiotherapy resistant; therefore, doses >60 Gy are needed in attempts to achieve local control after incomplete resection. Irradiation with protons or other charged particles seems beneficial in this curative situation. Chemotherapy is only possibly effective in mesenchymal chondrosarcoma, and is of uncertain value in dedifferentiated chondrosarcoma. Potential new systemic treatment targets are being discussed. The Oncologist 2008;13:320 -329

show abstract

Section: Systemic Treatmentmentioning

confidence: 99%

Section: Rare Chondrosarcoma Subtypesmentioning

confidence: 99%

The Clinical Approach Towards Chondrosarcoma

et al. 2008

View full text Add to dashboard Cite

show abstract

“…In a multicenter study conducted by Grimer et al,4 no difference in overall survival was observed in patients under 60 years without metastasis at diagnosis whether they received chemotherapy or not ( p = 0.09). The authors have no sufficient explanation for the lack of benefit of systemic treatment.…”

Section: Discussionmentioning

confidence: 84%

“…Our aim was to find pre‐treatment serum markers as independent factors for estimation of survival in chondrosarcoma patients. Several prognostic factors have been described in previous reports: Pelvic location, increased age, metastasis at diagnosis,4 pathological fracture,13 advanced tumor stage (AJCC III or IV), and size (tumors larger than 8 cm)2 and inadequate resection margins 14…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

C‐reactive protein: An independent predictor for dedifferentiated chondrosarcoma

Nemecek

Funovics

Hobusch

et al. 2018

Journal Orthopaedic Research

View full text Add to dashboard Cite

Dedifferentiated chondrosarcoma is a rare primary bone malignancy with a very poor prognosis. The aim of the study was to identify pretreatment serum markers as prognostic factors for the overall survival (OS) of patients with dedifferentiated chondrosarcoma. We retrospectively reviewed 33 patients with histologically confirmed dedifferentiated chondrosarcoma treated at our department from 1977 to 2015. Kaplan‐Meier estimation, uni‐ and multivariable Cox proportional hazard model were performed to evaluate the association between serum markers such as the C‐reactive protein and OS. In univariable analysis, CRP was strongly associated with OS (HR 1.35; 95%CI 1.13–1.61; p = 0.001). This association prevailed after adjustment for AJCC tumor stage (HR 1.31; 95%CI 1.02–1.57; p = 0.031) in multivariable analysis. In conclusion, our data gave evidence that baseline CRP is an independent predictor for OS in patients with dedifferentiated chondrosarcoma. CRP could be exploited for the clinical prediction of this disease in the future. © 2018 The Authors. Journal of Orthopaedic Research® Published by Wiley Periodicals, Inc. on behalf of Orthopaedic Research Society. J Orthop Res 36:2797–2801, 2018.

show abstract